Amgen Inc.
$252.25B- Market cap
- $206.78B
- Debt
- +$54.60B
- Cash
- −$9.13B
Capital structure 79% equity / 21% debt · EV / Revenue 6.86x · EV proxy / EBITDA proxy 17.71x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $206.78B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: AMGN stock price at discount vs LLY $382.47 current versus $696.31 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LLY's multiple
Implied fair value · at AMGN's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Multiple discount
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 79% equity / 21% debt · EV / Revenue 6.86x · EV proxy / EBITDA proxy 17.71x
Capital structure 96% equity / 4% debt · EV / Revenue 16.76x
LLY carries the larger enterprise value at $1.09T against $252.25B; AMGN trades on the lower EV / Revenue multiple (6.86x vs 16.76x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Amgen Inc. · implied price per share
Bear
$121.60
Base
$161.79
Bull
$216.01
ELI LILLY AND COMPANY · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
REGENERON PHARMACEUTICALS, INC.
AMGN vs REGN
BIOGEN INC.
AMGN vs BIIB
VERTEX PHARMACEUTICALS INC / MA
AMGN vs VRTX
Gilead Sciences, Inc.
AMGN vs GILD
Moderna, Inc.
AMGN vs MRNA
Pfizer Inc.
AMGN vs PFE
Merck & Co., Inc.
AMGN vs MRK
Johnson & Johnson
AMGN vs JNJ
AbbVie Inc.
AMGN vs ABBV
Bristol-Myers Squibb Company
AMGN vs BMY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AMGN can sustain double-digit growth while narrowing LLY’s profitability gap, then AMGN looks attractive on relative valuation because it trades at far lower P/E, P/S, and EV/EBITDA multiples than LLY; otherwise, LLY’s stronger fundamentals may justify most of the premium.
AMGN trades at a steep discount to LLY on both earnings and sales-based multiples, with the P/E gap especially large. However, the market is rewarding LLY for much faster growth and superior margins, so the valuation discount likely reflects business quality as well as sentiment.
Supporting Metrics